ModifiedBlue Cross Blue Shield - New MexicoPolicy CPCPLAB045

Pathogen Panel Testing

Customize your policy alerts

Sign up for Blue Cross Blue Shield - New Mexico Policy CPCPLAB045 alerts

Get alerted when Policy CPCPLAB045 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Outpatient laboratory reimbursement and coverage criteria for multiplex molecular pathogen panel testing for Blue Cross Blue Shield of New Mexico members; applies to providers submitting claims for outpatient testing.

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifiedBlue Cross Blue Shield - New MexicoPolicy CPCPLAB045

Pathogen Panel Testing

Customize your policy alerts

Sign up for Blue Cross Blue Shield - New Mexico Policy CPCPLAB045 alerts

Get alerted when Policy CPCPLAB045 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerBlue Cross Blue Shield - New Mexico

PolicyPathogen Panel Testing

Policy CodePolicy CPCPLAB045

Change TypeMaterial wording clarification + code list updates

Effective DateAug 1, 2025

Last ReviewAug 1, 2025

Next Review Date

Key ActionFor outpatient respiratory panels, bill only multiplex PCR panels with up to 5 targets for symptomatic patients and use the updated CPT/Category III/U codes listed in the policy.

SourceLink

POLICY UPDATE CHANGES

Added codes 0590U and 0593U effective 10/01/2025.

Added codes 0202U, 0223U, 0225U, and 0531U.

Added new CPT code 0528U effective 01/01/2025.

Policy clarified to be specific to testing in the outpatient setting and reimbursement statements adjusted accordingly.

Added codes 0441U, 0442U, 0480U, 0504U and removed codes 0151U, 0416U.

Removed statement that molecular-based panel testing for general screening of microorganisms is not reimbursable, and instead clarified specific not-reimbursable examples and additions.

up to 5respiratory pathogens reimbursable

6+respiratory pathogens non-reimbursable

40+procedure/billing codes listed

outpatient onlypolicy setting

multiplecodes added/updated

updatedreferences cited

Coverage Criteria for Multiplex Molecular Panels

Reimbursable outpatient respiratory multiplex PCR panels

Covered when ALL of the following are met

Outpatient respiratory panel (<=5 targets): Multiplex PCR-based panel testing (up to 5 respiratory pathogens) may be reimbursable for individuals who are displaying signs and symptoms of a respiratory tract infection, including at least one of the following: a temperature ≥102° F; pronounced dyspnea; tachypnea; or tachycardia.up to 5 targets

Policy applies only to outpatient testing

This policy addresses reimbursement for multiplex molecular pathogen panels used in the outpatient setting. Multiplex PCR-based respiratory panels that detect up to 5 respiratory pathogens may be reimbursable when performed on symptomatic individuals and when ALL coverage criteria are met, including at least one qualifying clinical sign: temperature ≥102°F, pronounced dyspnea, tachypnea, or tachycardia. Multiplex PCR-based panels that detect 6 or more respiratory pathogens are not reimbursable.

In addition to respiratory panels, molecular panel testing of other specimen types is specifically addressed. Panel testing of pathogens in cerebrospinal fluid (CSF) is not reimbursable, and molecular detection–based panel testing of pathogens in the blood is not reimbursable. The policy also identifies certain molecular panels for urine (for diagnosis of urinary tract infections) and wound infection testing as not reimbursable; examples cited in the document include the GENETWORx Molecular PCR UTI Test and GENETWORx PCR Wound Testing. Policy updates and code additions affecting outpatient reimbursement are summarized in the policy history and should be reviewed when billing.

The Plan considers molecular-based panel testing performed for general screening of microorganisms to be not reimbursable. The policy history and examples highlight tests that have been identified as general screening modalities and therefore subject to denial under the policy. Specific examples called out in the document include broad molecular screening platforms such as MicroGenDX qPCR+NGS and previously referenced specimen-specific screening panels (for example, certain vaginal swab or urine screening panels).

The policy revisions and historical notes (see Policy Update History) reflect changes in how general screening panels are enumerated and how reimbursable examples are handled; providers should consult the policy's not-covered list and update history when determining whether a given molecular panel performed for broad organism screening is eligible for reimbursement.

Use of molecular-based panel testing for the specimen types and broad screening indications listed in this policy is considered not reimbursable by the Plan. Specifically, the Plan does not reimburse: multiplex PCR-based panel testing of 6 or more respiratory pathogens; panel testing of pathogens in CSF; molecular detection–based panel testing of pathogens in the blood; molecular detection–based panel testing of urine pathogens for diagnosis of urinary tract infections (for example, GENETWORx Molecular PCR UTI Test); and molecular-based panel testing to screen for or diagnose wound infections (for example, GENETWORx PCR Wound Testing).

Providers should ensure testing and billing align with the policy’s outpatient-only scope and with the specific CPT/HCPCS/U-code assignments listed in the reimbursement section and update history to avoid claim denials.

Historically, the Plan has identified a set of molecular-based panel tests used for general screening of microorganisms as not reimbursable. The policy update history documents examples and revisions: earlier iterations explicitly listed specimen-specific screening panels (e.g., vaginal swab panels such as SmartJane™, urine screening panels such as UroSwab®) and later reinstated explicit non-reimbursable examples such as MicroGenDX qPCR+NGS. The policy history also records other example additions (e.g., GENETWORx assays) and clarifications to the outpatient-focused scope.

These historical entries are intended to guide providers about the types of broad screening molecular panels the Plan has previously determined are outside of reimbursable outpatient testing.

Indications Where Testing May Be Covered

Symptomatic outpatient respiratory tract infection with qualifying signs for outpatient multiplex respiratory panel (<=5 targets)

Symptomatic outpatient respiratory tract infection with qualifying signs: Patient is symptomatic with a respiratory tract infection and has at least ONE of: temperature ≥102° F; pronounced dyspnea; tachypnea; or tachycardia.

Diagnostic testing for suspected sepsis, meningitis/encephalitis, respiratory infections, and other acute infectious syndromes where rapid pathogen identification may affect management

Covered when rapid pathogen identification may affect immediate clinical management

Acute infectious syndromes where rapid ID may affect management

Sepsis: Suspected sepsis/septic shock or bloodstream infection where rapid molecular pathogen detection may alter antimicrobial management (see Surviving Sepsis Campaign guidelines).

Not Covered Services and Panels

The following categories of molecular panel testing are identified as not covered under this outpatient-focused policy: multiplex PCR panels detecting ≥6 respiratory pathogens; cerebrospinal fluid (CSF) multiplex panels; molecular detection–based blood pathogen panels; urine molecular panels intended for UTI diagnosis; and molecular panels for wound infection diagnosis. The policy also clarifies that molecular-based panel testing performed for broad or general screening of microorganisms is not reimbursable, with specific examples provided in the policy history.

Providers submitting outpatient claims for panel tests should compare the test purpose, specimen type, and code(s) billed against this not-covered list to determine likely reimbursement outcomes.

Examples of molecular-based panel testing performed for general screening of microorganisms that the policy identifies as not reimbursable include broad screening platforms referenced in the policy history. The document specifically names MicroGenDX qPCR+NGS as an example and notes prior examples of specimen-specific screening panels (such as certain vaginal swab and urine screening tests) that have been discussed in earlier versions. Providers should treat similar broad molecular screening assays as non-reimbursable unless otherwise specified.

This policy history and its enumerated examples are intended to aid billing decisions; when in doubt, confirm whether a test is being billed as a diagnostic/outpatient clinically indicated assay versus a general screening service.

Denial Risk

Procedure, CPT, HCPCS and U-Code Guidance

Procedure/CPT and HCPCS codes referencedmixed

87154
87483
87631
87632
87633
87636
87637
0068U
0086U
0109U

1–10 of 35

1/4

Reimbursement CPT/U codes (added and removed)mixed

0590U	code added (document lists as added)
0593U	code added (document lists as added)
0202U	code added
0223U	code added
0225U	code added
0531U	code added
0528U	new CPT code added effective 01/01/2025
0441U	code added
0442U	code added
0480U	code added

1–10 of 13

1/2

inv-08: Respiratory panel target count — reimbursement thresholds

Reimbursable target countMultiplex PCR-based respiratory panels with up to 5 pathogen targets are eligible for outpatient reimbursement when clinical criteria are met

Non-reimbursable target countMultiplex PCR-based respiratory panels with 6 or more pathogen targets are not reimbursable

Setting restrictionPolicy and target-count reimbursement rules apply only to outpatient testing

Provider Responsibilities, Billing, and Documentation

Prior Authorization

Outpatient respiratory panel reimbursement limited to ≤5 targets with symptomatic patient

Reimbursement for outpatient multiplex PCR respiratory panels is limited to panels detecting up to five respiratory pathogens when the patient is symptomatic and meets at least one listed qualifying sign.

Covered only in the outpatient setting.
At least one qualifying sign required: temperature ≥102°F, pronounced dyspnea, tachypnea, or tachycardia.
Panels detecting more than 5 respiratory targets are not reimbursable.

Billing Rule

Use updated CPT Category III/U codes for outpatient panel claims

Ordering and Setting Requirements

Step Therapy

Confirm plan/product‑specific reimbursement applicability before ordering

Review Plan documents and product‑specific reimbursement criteria before ordering; this policy applies specifically to outpatient testing and may not apply to every product or benefit.

The Plan has implemented lab management reimbursement criteria; not all requirements apply to each product — verify member’s benefit.
Providers are urged to review Plan documents for eligible coverage for services rendered.

Step Therapy

Ensure orders and claims are for outpatient setting to meet policy applicability

Ensure the order and billing indicate the outpatient setting since reimbursement statements and code applicability in the policy are specific to outpatient testing.

Policy statement: 'This policy is specific to testing in the outpatient setting.'
If the testing is not outpatient, the policy criteria do not apply.

Background and Definitions

Multiplex molecular panels are assays that simultaneously detect multiple pathogen targets and can provide rapid identification of causative organisms for a range of syndromes. These platforms have been developed for respiratory infections, central nervous system infections (meningitis/encephalitis), bloodstream infections/sepsis, urinary tract infections, and wound infections.

When used appropriately in the outpatient diagnostic context, targeted multiplex respiratory panels (up to 5 targets) can support clinical management of symptomatic patients. However, clinical utility varies by syndrome and specimen type; the policy references systematic reviews and guideline literature (for example, evidence addressing meningitis/encephalitis and sepsis-related multiplex assays) to inform appropriate use. Because the Plan’s reimbursement policy is limited to the outpatient setting, providers should apply clinical judgment and relevant guidance to determine the appropriateness of multiplex testing for cases where rapid pathogen identification may affect patient management.

inv-19: Definition of multiplex PCR-based panel testing

DefinitionMolecular assays that simultaneously detect multiple pathogen targets (e.g., respiratory, blood, CSF, urine, wound panels) using PCR or other molecular detection methods

Typical useRapid identification of multiple respiratory pathogens to inform clinical management in symptomatic patients

Examples of specimen types

Frequency and Repeat Testing Limits

inv-24: Frequency limits (inventory placeholder)

Frequency limit summaryNo numeric repeat-test frequency limit specified in the policy for multiplex panels

Applicable periodPolicy applies to outpatient testing; any frequency considerations should follow outpatient coverage rules and clinical justification

Documentation requirementProviders must submit appropriate clinical documentation supporting medical necessity for repeat testing; claims remain subject to code-edit review

Policy Revision History

2025-08-01effective_dateLatest

Policy effective date updated to 08/01/2025 and summary of changes revised to include addition of codes 0590U and 0593U (effective 10/01/2025).

2025-01-23codes_added

Added codes 0202U, 0223U, 0225U, and 0531U (noted in summary of changes with date 04/15/2025).

2024-11-19code_added

Policy Summary

PayerBlue Cross Blue Shield - New Mexico

PolicyPathogen Panel Testing

Policy CodePolicy CPCPLAB045

Change TypeMaterial wording clarification + code list updates

Effective DateAug 1, 2025

Last ReviewAug 1, 2025

Next Review Date

Key ActionFor outpatient respiratory panels, bill only multiplex PCR panels with up to 5 targets for symptomatic patients and use the updated CPT/Category III/U codes listed in the policy.

SourceLink

On This Page

Meningitis/Encephalitis: Suspected central nervous system infection where a meningitis/encephalitis multiplex PCR panel is being used for etiologic diagnosis guided by relevant systematic reviews and IDSA guidance.

Acute respiratory infections where rapid multiplex respiratory testing could affect clinical decisions (antimicrobial use, isolation), consistent with cited respiratory diagnostics literature.

Non‑reimbursable panels: ≥6 respiratory targets and specified specimen‑type panels

Multiplex PCR-based panel testing of six or more respiratory pathogens and certain specimen-type panels (CSF, blood, urine for UTI, wound infection panels, and broad general‑screening molecular panels) are not reimbursable by the Plan.

Multiplex PCR-based panel testing of 6 or more respiratory pathogens is not reimbursable.
Multiplex PCR-based panel testing of pathogens in cerebrospinal fluid (CSF) is not reimbursable.
Molecular detection-based panel testing of pathogens in the blood is not reimbursable.
Molecular detection-based panel testing of urine pathogens for UTI diagnosis (e.g., GENETWORx Molecular PCR UTI Test) is not reimbursable.
Molecular-based panel testing to screen for or diagnose wound infections (e.g., GENETWORx PCR Wound Testing) is not reimbursable.
Molecular-based panel testing for general screening of microorganisms (e.g., MicroGenDX qPCR+NGS) is not reimbursable.

Use the updated CPT Category III and proprietary U‑codes listed in the policy when billing outpatient multiplex PCR panel tests; several codes were added to the reimbursable list in recent updates.

Added codes include (examples from updates): 0202U, 0223U, 0225U, 0528U, 0531U, 0590U, 0593U, 0441U, 0442U, 0480U, 0504U.
Ensure the code used corresponds to the panel tested and the outpatient setting per policy guidance.

Note

Verify product‑specific outpatient applicability before ordering or billing

(Placeholder action) Review the plan’s reimbursement section and code lists to confirm whether a specific multiplex panel and its specimen type are covered for outpatient billing.

Check plan documents for product‑specific applicability before ordering or billing.
Confirm the test’s specimen type and target count align with policy exclusions and coverage statements.

Documentation Required

Document clinical indication and verify coverage for unlisted panels

(Placeholder action) If a tested panel or code is not listed in the policy, obtain and retain documentation demonstrating clinical indication and check for prior authorization or medical policy guidance before submission.

Retain clinical documentation supporting the outpatient symptomatic indication when billing.
Be prepared to provide additional documentation upon request to support medical necessity.

Documentation Required

Submit accurate documentation and furnish additional records upon request

Providers must submit accurate documentation of services performed and, upon request, provide additional documentation to support claims.

Submit claims using valid code combinations from HIPAA‑approved code sets and industry coding guidelines.
Upon request, submit any additional documentation to support the claim.

Documentation Required

Ensure outpatient setting is documented and billing codes match policy list

Document that testing occurred in the outpatient setting and use the specific CPT/HCPCS/U‑code listed in the policy for the panel billed to align coding with the updated reimbursement applicability.

Policy is specific to testing in the outpatient setting — ensure the claim reflects outpatient setting.
Select the policy‑listed code that corresponds to the panel; recent updates added and removed specific codes, so use the current list.

Denial Risk

Claims subject to code‑edit protocols and plan review — inaccurate coding/documentation risks denial

Claims are subject to code edit protocols, plan documents, provider contract terms, and coding software logic; inaccurate documentation, invalid code combinations, or failure to follow listed codes may trigger claim review or denial.

Claims should be coded per standard coding guidelines (CPT, HCPCS, ICD‑10) and submitted using valid code combinations.
Inaccurate documentation or billing codes inconsistent with the policy’s reimbursable list may result in denial or review.

Denial Risk

Denial risk: general‑screening molecular panels (e.g., qPCR+NGS)

Molecular‑based panel testing performed for general screening of microorganisms (examples cited such as MicroGenDX qPCR+NGS) is identified as not reimbursable and poses a denial risk if billed.

General‑screening panels (e.g., broad qPCR+NGS tests) are specifically noted as not reimbursable.
Billing these tests despite the policy exclusions may result in claim denials.

Respiratory specimens (nasopharyngeal swab, etc.), but policy excludes some specimen types (CSF, blood, urine) from reimbursement for panel testing

inv-20: Meningitis/Encephalitis panel

DefinitionA multiplex PCR assay intended for etiologic diagnosis of central nervous system infections (meningitis/encephalitis) by detecting multiple pathogens in CSF specimens

Evidence baseReferenced by a systematic review and diagnostic test accuracy meta-analysis of the BioFire FilmArray Meningitis/Encephalitis panel (Trujillo-Gómez et al., 2022)

Guidance referenceManagement of encephalitis guidance from the Infectious Diseases Society of America (Tunkel et al., 2008) is cited in support of panel context

inv-21: Sepsis molecular panels

DefinitionMolecular panels designed to rapidly detect bloodstream pathogens to support sepsis management (e.g., assays performed on blood/blood-culture specimens)

Example assaysMagicplex Sepsis Real-time Test (Seegene) and T2Bacteria Panel (T2Biosystems) are cited as vendor assays referenced in the policy

Guideline supportSurviving Sepsis Campaign guidelines and pediatric sepsis guidelines are cited as context for use of rapid sepsis diagnostics

Added new CPT code 0528U effective 01/01/2025 (documented 11/19/2024).

2024-10-30policy_clarification_and_code_updates

Policy language revised to specify outpatient testing (removed leading 'In the outpatient setting.') and reimbursement information updated by adding codes 0441U, 0442U, 0480U, 0504U and removing codes 0151U and 0416U; references updated and literature review performed.

2024-03-01code_added

Added code 0416U (documented 03/01/2024).

2023-11-01policy_revision

Document updated with literature review and reimbursement information clarified to identify specific non-reimbursable general screening tests and examples (e.g., SmartJane™, UroSwab®, MicroGenDX qPCR+NGS); GENETWORx tests added as examples.

2022-11-01new_policy

Policy originally created and published (new policy as of 11/01/2022).